Analysts expect Passage BIO, Inc. to report revenue of 0.00 for Q1 26, against a range of 0.00 to 0.00. The most recent reported quarter, Q4 25, came in at 0.00.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - |
| High Estimate | 1.67 M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Low Estimate | 1.55 M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consensus Estimate | 1.61 M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analysts expect Passage BIO, Inc. to report earnings per share of -2.51 for Q3 26, against a range of -2.70 to -2.32. The most recent reported quarter, Q2 26, came in at -2.44, a 7.5% miss against the -2.27 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -6.20 | -4.00 | -5.00 | -2.96 | -2.44 | -4.09 | -2.36 | -2.44 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -4.07 | -3.95 | -4.01 | -4.11 | -2.50 | -2.47 | -2.54 | -2.16 | -2.32 | -2.35 | -2.26 | -2.16 | -2.07 | -2.81 | -2.12 | -2.05 | ||||||||||
| Low Estimate | -4.73 | -4.31 | -4.83 | -4.43 | -2.66 | -2.81 | -2.72 | -2.38 | -2.70 | -2.51 | -2.54 | -2.50 | -2.51 | -3.03 | -2.44 | -2.31 | ||||||||||
| Consensus Estimate | -4.40 | -4.13 | -4.42 | -4.27 | -2.58 | -2.64 | -2.63 | -2.27 | -2.51 | -2.43 | -2.40 | -2.33 | -2.29 | -2.92 | -2.28 | -2.18 |